How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/klebsiella-pneumoniae-peritonitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Klebsiella Pneumoniae Peritonitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Klebsiella Pneumoniae Peritonitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Klebsiella Pneumoniae Peritonitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Klebsiella Pneumoniae Peritonitis
Pfizer · 3 drugs in Klebsiella Pneumoniae Peritonitis
Bristol-Myers Squibb · 2 drugs in Klebsiella Pneumoniae Peritonitis
Pai Holdings Pharm · 2 drugs in Klebsiella Pneumoniae Peritonitis
National Institutes of Health Clinical Center (CC) · 1 drug in Klebsiella Pneumoniae Peritonitis
Novartis · 1 drug in Klebsiella Pneumoniae Peritonitis
Sterimax · 1 drug in Klebsiella Pneumoniae Peritonitis
Tel-Aviv Sourasky Medical Center · 1 drug in Klebsiella Pneumoniae Peritonitis
University Hospital, Lille · 1 drug in Klebsiella Pneumoniae Peritonitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Klebsiella Pneumoniae Peritonitis
Dr Reddys Labs Inc · 1 drug in Klebsiella Pneumoniae Peritonitis
Generic (originally Roche) · 1 drug in Klebsiella Pneumoniae Peritonitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Klebsiella Pneumoniae Peritonitis:

Cite this brief

Drug Landscape (2026). Klebsiella Pneumoniae Peritonitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-pneumoniae-peritonitis. Accessed 2026-06-10.

Klebsiella Pneumoniae Peritonitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing